

# AGM Voting

RNS Number : 56300

Novacyt S.A.

13 June 2022

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

AGM voting

Paris, France and Camberley, UK - 13 June 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as an open online meeting at 2pm CEST/1pm BST on 21 June 2022. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.

Under French law, for the meetings to be quorate at the first attempt, at least 20% of the shareholders must vote on the ordinary resolutions and 25% of the shareholders must vote on the extraordinary resolutions. Shareholders are therefore strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the notice convening the meeting, copies of which are available in the General Meetings section on the Company's website at [www.novacyt.com/investors](http://www.novacyt.com/investors).

Following registration and proof of shareholding, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish. Following the meeting, a recording of the AGM will be available on the Company's website at [www.novacyt.com/investors](http://www.novacyt.com/investors). Shareholders who have already voted (through a proxy, using the AGM or Votaccess portals) will be allowed to attend the AGM but will not be able to vote twice.

- End -

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABKBBBDBKBKAD